Randomized Comparison of Oral P2Y₁₂-Receptor Inhibitor Loading Strategies for Transitioning From Cangrelor: The...

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Intravenous cangrelor effectively inhibits platelets during percutaneous coronary intervention (PCI), reducing ischemic risk.
• Transitioning from cangrelor to oral P2Y12 inhibitors like clopidogrel or prasugrel is complicated by drug interactions, often requiring a washout period.
• Prasugrel's long half-life suggests potential for early administration to maintain platelet inhibition.

Purpose of the Study:

• To evaluate if early loading with prasugrel during a cangrelor infusion provides adequate platelet inhibition post-cangrelor.
• To compare early prasugrel loading with ticagrelor and delayed clopidogrel loading in patients undergoing PCI.
• To determine if early prasugrel administration prevents a transient gap in platelet inhibition.

Main Methods:

• A randomized trial involving 110 P2Y12-receptor blocker-naive patients undergoing PCI with cangrelor.
• Patients were assigned to receive prasugrel 60 mg or ticagrelor 180 mg at cangrelor initiation, or clopidogrel 600 mg after cangrelor discontinuation.
• The primary endpoint was the proportion of patients achieving adequate platelet inhibition (absence of high on-treatment platelet reactivity) 1 hour after stopping cangrelor.

Main Results:

• High on-treatment platelet reactivity was observed in significantly fewer patients with early prasugrel (93.3%) or ticagrelor (95.6%) compared to delayed clopidogrel (65.0%) one hour after cangrelor cessation.
• Prasugrel demonstrated superiority over clopidogrel (p=0.003) in achieving adequate platelet inhibition.
• The 30-day incidence of ischemic and bleeding events was comparable across all treatment groups.

Conclusions:

• Administering prasugrel 60 mg at the start of a 2-hour cangrelor infusion achieves sufficient platelet inhibition post-cangrelor.
• This early loading strategy effectively prevents the transient gap in platelet inhibition associated with oral loading after cangrelor discontinuation.
• The findings support a novel approach for P2Y12 inhibitor management in PCI patients receiving cangrelor.